Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Suppressing HIV Infection with Soybean Compound

By BiotechDaily International staff writers
Posted on 14 Aug 2013
A compound found in soybeans may become an effective HIV treatment, which could eliminate the drug resistance problems faced by current therapies, according to new research.

Genistein, derived from soybeans and other plants, shows potential in suppressing the HIV infection, according to Dr. Yuntao Wu, an infectious diseases and the department of molecular and microbiology professor with the George Mason University (Fairfax, VA, USA)-based US National Center for Biodefense.

Nevertheless, that does not mean individuals should begin eating large amounts of soy products. “Although genistein is rich in several plants such as soybeans, it is still uncertain whether the amount of genistein we consume from eating soy is sufficient to inhibit HIV,” Dr. Wu said.

Genistein functions by blocking the communication from a cell’s surface sensors to its insides and is known as a tyrosine kinase inhibitor. These sensors, located on the cell’s surface, tell the cell about its environment and also communicate with other cells. HIV uses some of these surface sensors to trick the cell to send signals inside. These signals change cell structure so that the virus can get inside and spread infection.

However, genistein blocks the signal and stops HIV from finding a way inside the cell. It takes a different approach than the conventional antiretroviral drug used to suppress HIV. “Instead of directly acting on the virus, genistein interferes with the cellular processes that are necessary for the virus to infect cells,” Dr. Wu noted. “Thus, it makes the virus more difficult to become resistant to the drug. Our study is currently it its early stage. If clinically proven effective, genistein may be used as a complement treatment for HIV infection.”

Dr. Wu sees possibilities in this plant-based approach, which may address drug toxicity issues as well. Because genistein is plant-derived, it may be able to sidestep drug toxicity, a common byproduct of the daily and lifelong pharmaceutical regimen faced by patients with HIV to keep the disease at bay, according to Dr. Wu. Typically, patients take a combination of multiple drugs to inhibit the virus. The frequency can lead to drug toxicity. Furthermore, HIV mutates and becomes drug-resistant.

Dr. Wu and his team are now looking for ways to determine how much genistein is required to inhibit HIV. Because there is a possibility that plants may not have high enough levels, this agent would need to be refined and further developed.

Related Links:

George Mason University




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.